NPPB and hydrops fetalis: In addition to targeted risk factor modification, individuals identified with an intermediate HF risk estimated with the PCP-HF tool may benefit from further risk stratification with sequential screening strategies with biomarkers (e.g. brain natriuretic peptide [BNP]) and/or imaging (e.g. left ventricular hypertrophy on echocardiogram) in an individualized, stepwise approach.